Stock ASND ASCENDIS PHARMA A/S
Add to a list
To use this feature you must be a member
Log inSign up

Company Ascendis Pharma A/S

Equities

ASND

US04351P1012

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-18 pm EDT 		5-day change 1st Jan Change
140.9 USD -0.90% Intraday chart for Ascendis Pharma A/S -6.72% +11.86%
Apr. 18 European Equities Traded in the US as American Depositary Receipts Flat in Thursday Trading MT
Apr. 02 JPMorgan Adjusts Ascendis Pharma A/S Price Target to $167 From $165, Maintains Overweight Rating MT

Business Summary

Ascendis Pharma A/S is a Denmark-based company that manufactures pharmaceutical products. The Company produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The Company operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark).

Number of employees: 879

Sales per Business

USD in Million2022Weight2023Weight Delta
Pharmaceutical Products
100.0 %
54 100.0 % 288 100.0 % +436.15%

Sales per region

USD in Million2022Weight2023Weight Delta
North America
71.9 %
46 86.3 % 207 71.9 % +346.54%
Asia
27.8 %
7 12.6 % 80 27.8 % +1,080.01%
Europe
0.3 %
1 1.1 % 1 0.3 % +61.94%

Managers

Managers TitleAgeSince
Jan Mikkelsen FOU
 Founder 65 06-08-31
Scott Smith DFI
 Director of Finance/CFO 50 16-08-07
Stina Singel CTO
 Chief Tech/Sci/R&D Officer 50 20-04-30
Kennett Sprogøe CTO
 Chief Tech/Sci/R&D Officer 46 07-11-30
Lotte Sønderbjerg ADM
 Chief Administrative Officer 62 07-11-30
Peter Rasmussen AUD
 Comptroller/Controller/Auditor 55 14-02-28
Flemming Steen Jensen PRN
 Corporate Officer/Principal 63 15-07-31
Michael Wolff Jensen LAW
 General Counsel 53 07-12-31

Members of the board

Members of the board TitleAgeSince
Jan Mikkelsen FOU
 Founder 65 06-08-31
Albert Cha CHM
 Chairman 51 14-10-31
Michael Wolff Jensen LAW
 General Counsel 53 07-12-31
Lisa Bright BRD
 Director/Board Member 56 17-03-31
Lars Holtug BRD
 Director/Board Member 66 18-11-01
William Fairey BRD
 Director/Board Member 59 22-08-31
Siham Imani BRD
 Director/Board Member 47 22-08-31

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 57,707,439 6,000,000 ( 10.40 %) 0 10.40 %

Shareholders

NameEquities%Valuation
RA Capital Management LP
17.51 %
10,107,400 17.51 % 1 528 M $
Artisan Partners Holdings LP
9.963 %
5,749,227 9.963 % 869 M $
Fidelity Management & Research Co. LLC
8.863 %
5,114,369 8.863 % 773 M $
Westfield Capital Management Co. LP
6.985 %
4,030,634 6.985 % 609 M $
Janus Henderson Investors US LLC
6.922 %
3,994,785 6.922 % 604 M $
T. Rowe Price Investment Management, Inc.
6.914 %
3,989,830 6.914 % 603 M $
Avoro Capital Advisor LLC
6.508 %
3,755,555 6.508 % 568 M $
Wellington Management Co. LLP
5.629 %
3,248,293 5.629 % 491 M $
Capital Research & Management Co. (International Investors)
3.780 %
2,181,268 3.780 % 330 M $
Massachusetts Financial Services Co.
2.633 %
1,519,219 2.633 % 230 M $
NameEquities%Valuation
Jan Mikkelsen
0.8903 %
423,279 0.8903 % 64 M $
Scott Smith
0.008449 %
4,017 0.008449 % 607 250 $
Kennett Sprogøe
0.006074 %
2,888 0.006074 % 436 579 $
Stina Singel
0.005740 %
2,729 0.005740 % 412 543 $
Fideuram Asset Management (Ireland) DAC
0.005302 %
2,521 0.005302 % 381 100 $
Michael Wolff Jensen
0.004061 %
1,931 0.004061 % 291 909 $
Flemming Steen Jensen
0.003908 %
1,858 0.003908 % 280 874 $
Lotte Sønderbjerg
0.003908 %
1,858 0.003908 % 280 874 $
Lars Holtug
0.001876 %
892 0.001876 % 134 844 $
Albert Cha
0.000822 %
391 0.000822 % 59 107 $

Company contact information

Ascendis Pharma A/S

Tuborg Boulevard 12

2900, Hellerup

+45 70 22 22 44

http://www.ascendispharma.com
address Ascendis Pharma A/S(ASND)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Sales per region

Ratings for Ascendis Pharma A/S

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
132.1 EUR
Average target price
166.7 EUR
Spread / Average Target
+26.18%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
ASCENDIS PHARMA A/S Stock Ascendis Pharma A/S
+11.86% 8.05B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-3.30% 102B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+1.79% 96.07B
ARGENX SE Stock argenx SE
-1.54% 21.66B
BIONTECH SE Stock BioNTech SE
-18.35% 20.77B
GENMAB A/S Stock Genmab A/S
-7.45% 18.53B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-40.31% 16.91B
BEIGENE, LTD. Stock BeiGene, Ltd.
-26.84% 13.79B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+0.59% 13.33B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+20.86% 10.94B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. ASND Stock
  4. Company Ascendis Pharma A/S